Pulse Biosciences Files 8-K on Shareholder Votes & Other Events

TL;DR

Pulse Biosciences filed an 8-K for Sept 30th - shareholder votes and other events are on the table.

AI Summary

Pulse Biosciences, Inc. filed an 8-K on October 1, 2025, reporting on events that occurred on September 30, 2025. The filing indicates a submission of matters to a vote of security holders and other events. The company, formerly known as Electroblate, Inc., is incorporated in Delaware and headquartered in Hayward, California.

Why It Matters

This filing signals important corporate actions, potentially including shareholder decisions on key matters or significant operational updates that could impact the company's direction.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting on corporate events and does not inherently indicate significant financial distress or immediate risk.

Key Numbers

• 001-37744 — SEC File Number (Identifies the company's filing history with the SEC.)
• 46-5696597 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Pulse Biosciences, Inc. (company) — Registrant
• Electroblate, Inc. (company) — Former company name
• September 30, 2025 (date) — Date of earliest event reported
• October 1, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Hayward, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
• $15.65 — of the Awards has an exercise price of $15.65 per share, a ten year term and will ves

Filing Documents

• plse20250929_8k.htm (8-K) — 39KB
• 0001437749-25-030184.txt ( ) — 168KB
• plse-20250930.xsd (EX-101.SCH) — 3KB
• plse-20250930_def.xml (EX-101.DEF) — 11KB
• plse-20250930_lab.xml (EX-101.LAB) — 15KB
• plse-20250930_pre.xml (EX-101.PRE) — 11KB
• plse20250929_8k_htm.xml (XML) — 3KB

07

ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. On September 30, 2025, Pulse Biosciences, Inc. (the "Company") held, via live audio webcast, a special meeting of stockholders (the "Special Meeting"). Stockholders of record at the close of business on August 25, 2025 (the "Record Date") were entitled to vote at the Special Meeting. Of the common stock eligible to be voted, 53,011,701 shares were represented at the Special Meeting, either in person or by proxy, constituting a quorum. Stockholders were asked to vote on the following items at the Special Meeting (the "Proposals"): 1. To approve an amendment to the Company's 2017 Equity Incentive Plan (the "Equity Plan") to increase the number of shares of the Company's common stock issuable under the Equity Plan by two million shares and to change the definition of "Consultant" found in the Equity Plan so that the Company can grant equity awards under the Equity Plan to any natural person rendering bona fide services to the Company while engaged by a third-party, such as a payrolling service or employer of record; and 2. Both Proposals were approved at the Special Meeting by the requisite vote of the Company's stockholders in accordance with the recommendation of the Company's Board of Directors. The voting results for each of these Proposals are detailed below: Proposal 1. Amendment of the Equity Plan For Against Abstained Broker Non-votes 50,247,945 2,753,901 9,855 N/A Proposal 2. Ratification of Awards

01

ITEM 8.01 OTHER EVENTS On September 30, 2025, the Company's stockholders ratified the grant of options awarded by the Company to certain Company directors on August 9, 2024, including one who is presently also serving as the Company's Chief Executive Officer, Paul A. LaViolette, to purchase up to 600,000 shares of Company common stock, in aggregate (the "Awards"). Each of the Awards has an exercise price of $15.65 per share, a ten year term and will vest as follows: one fourth (1/4th) of the shares subject to these Awards will vest on the date of the Company's next annual meeting and the remaining three fourths (3/4ths) of the shares subject to these Awards will vest on a monthly basis thereafter, subject to the director and/or officer, as applicable, continuing to serve as a member of the Strategic Advisor Committee through each vesting date. Below is a summary of the Awards granted to the Company's directors on August 9, 2024, which were ratified at the Special Meeting: Name and Position Number of Options to Purchase Shares of Common Stock Reporting Executive and/or Director Paul A. LaViolette 200,000 Manmeet S. Soni 200,000 Mahkam Zanganeh 200,000 Total 600,000 Mr. LaViolette became the Company's President and Chief Executive Officer on January 9, 2025, and he continues to serve as an ex officio member of the Strategic Advisory Committee. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: October 1, 2025 By: /s/ Jon Skinner Jon Skinner Chief Financial Officer (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR